TrialJournal of diabetes investigation2018

Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.

Arihiro Kiyosue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.